Format

Send to

Choose Destination
Radiother Oncol. 2013 Jun;107(3):434-41. doi: 10.1016/j.radonc.2013.03.027. Epub 2013 May 14.

Prediction of response to radiotherapy in the treatment of esophageal cancer using stem cell markers.

Author information

1
University of Groningen, University Medical Center Groningen, Department of Surgery, Section of Surgical Oncology, The Netherlands.

Abstract

BACKGROUND AND PURPOSE:

In this study, we investigated whether cancer stem cell marker expressing cells can be identified that predict for the response of esophageal cancer (EC) to CRT.

MATERIALS AND METHODS:

EC cell-lines OE-33 and OE-21 were used to assess in vitro, stem cell activity, proliferative capacity and radiation response. Xenograft tumors were generated using NOD/SCID mice to assess in vivo proliferative capacity and tumor hypoxia. Archival and fresh EC biopsy tissue was used to confirm our in vitro and in vivo results.

RESULTS:

We showed that the CD44+/CD24- subpopulation of EC cells exerts a higher proliferation rate and sphere forming potential and is more radioresistant in vitro, when compared to unselected or CD44+/CD24+ cells. Moreover, CD44+/CD24- cells formed xenograft tumors faster and were often located in hypoxic tumor areas. In a study of archival pre-neoadjuvant CRT biopsy material from EC adenocarcinoma patients (N=27), this population could only be identified in 50% (9/18) of reduced-responders to neoadjuvant CRT, but never (0/9) in the complete responders (P=0.009).

CONCLUSION:

These results warrant further investigation into the possible clinical benefit of CD44+/CD24- as a predictive marker in EC patients for the response to chemoradiation.

KEYWORDS:

Cancer stem cells; Chemoradiotherapy; Esophageal cancer; Radiotherapy; Response

PMID:
23684587
DOI:
10.1016/j.radonc.2013.03.027
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center